SUSIE LEE: Open Payments
NPI 1194141523 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,717 in 120 payments from 21 companies in 2025. Trend: 2023 $1,452 · 2024 $2,173 · 2025 $4,717
Food & beverage: $2,829Travel & lodging: $1,357Education: $357Consulting: $175
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $1,813 |
| Novartis Pharmaceuticals Corporation | 30 | $638 |
| Astellas Pharma US Inc | 6 | $365 |
| Janssen Biotech, Inc. | 10 | $264 |
| Alexion Pharmaceuticals, Inc. | 5 | $257 |
| AstraZeneca Pharmaceuticals LP | 11 | $236 |
| SOBI, INC | 5 | $226 |
| GENZYME CORPORATION | 7 | $203 |
| BeOne Medicines USA, Inc. | 9 | $196 |
| Incyte Corporation | 4 | $99 |
Products named: Fabhalta, CALQUENCE, ULTOMIRIS, BRUKINSA, TECVAYLI, Doptelet, AYVAKIT, SCEMBLIX.
Industry payments across CA — which companies pay providers there.
